ACRO Biomedical Co. has announced that its ABCcolla Collagen Ophthalmic Matrix has received regulatory approval from Taiwan's Ministry of Health and Welfare (MoHW). This milestone marks a significant advancement in regenerative medicine and provides new hope for millions awaiting corneal transplants worldwide.
ABCcolla Collagen Ophthalmic Matrix is the world's first and only product to utilise supercritical carbon dioxide decellularization technology, ensuring the complete removal of cells and impurities from animal-derived corneal tissue while preserving its intact collagen scaffold. This innovative approach enhances biocompatibility, biodegradability, and tissue regeneration. The product has received patents in 15 countries and won the Silver Award at the 2023 National Pharmaceutical Technology R&D Awards. Notably, there are currently no similar products available in the Taiwanese market.
With an ageing global population, increasing prevalence of corneal diseases, and rising awareness of vision health, the demand for corneal transplantation and related products is expected to grow steadily. By advancing this breakthrough technology, ACRO Biomedical aims to reduce dependency on donated corneas and restore sight for more patients worldwide.
ACRO Biomedical has developed this product using porcine corneas, which closely resemble human corneal structure. Once all cellular components are removed, the material can serve as a biocompatible alternative to donated human corneas, reducing the risk of immune rejection.
